Quinoline Derivatives Targeting Fibronectin Receptor Alpha-5-Beta-1
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-angiogenic therapies lack effective inhibitors for the fibronectin receptor alpha-5-beta-1, which plays a critical role in angiogenesis and is associated with various pathological conditions such as cancer, diabetic retinopathy, and inflammatory processes.
Innovation Solution
Development of novel quinoline derivatives with specific side-chains that effectively block integrins, particularly the fibronectin receptor alpha-5-beta-1, offering improved solubility properties compared to similar analogs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-angiogenic therapies are used, then general angiogenesis inhibition is achieved, but effective inhibition of the fibronectin receptor alpha-5-beta-1 is lacking
Solution Approach 1:
The patent applies local quality by designing quinoline derivatives with specific side-chain configurations (R1, R2, R3, R4, R5 groups) that are optimized to interact with particular amino acid residues in the fibronectin receptor alpha-5-beta-1 binding site. This localized molecular design enables selective inhibition of this specific integrin receptor while maintaining general anti-angiogenic activity, resolving the contradiction between target specificity and inhibition effectiveness.
2Reliability
If novel quinoline derivatives with specific side-chains are developed, then effective blocking of integrins is achieved, but solubility properties must be improved compared to similar analogs
Solution Approach 1:
The patent employs parameter changes by systematically modifying the chemical properties of the quinoline core structure through various substituent groups (hydroxyl, carboxyl, amino, alkyl groups at different positions). These parameter changes in molecular structure directly affect both the biological activity (integrin blocking) and physical properties (solubility), allowing optimization of both characteristics simultaneously.
3Reliability
If the fibronectin receptor alpha-5-beta-1 is effectively inhibited, then angiogenesis is blocked, but therapeutic application requires demonstration of safety and efficacy in pathological conditions
Solution Approach 1:
The patent incorporates feedback mechanisms by using the fibronectin receptor alpha-5-beta-1 as a measurable biomarker to monitor therapeutic response. The assay methods described provide quantitative feedback on receptor inhibition levels, which can be correlated with angiogenesis blockade and clinical outcomes in pathological conditions such as cancer, diabetic retinopathy, and inflammatory processes, thereby verifying therapeutic benefits.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A compound of formula (I) as well as pharmaceutically acceptable salts thereof. A pharmaceutical composition comprising a therapeutically effective amount of the compound. The compound is useful for the treatment of cancer, diabetic retinopathy, age-related macular degeneration, inflammation, stroke, ischemic myocardium, atherosclerosis, macular edema or psoriasis.